首页 | 本学科首页   官方微博 | 高级检索  
     


Enhanced fluid management with continuous venovenous hemofiltration in pediatric respiratory failure patients receiving extracorporeal membrane oxygenation support
Authors:Nancy G. Hoover  Michael Heard  Christopher Reid  Scott Wagoner  Kristine Rogers  Jason Foland  Matthew L. Paden  James D. Fortenberry
Affiliation:(1) Department of Pediatrics, Walter Reed Army Medical Center, Washington, DC, USA;(2) Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA;(3) Division of Critical Care Medicine, Children’s Healthcare of Atlanta at Egleston, 1405 Clifton Road NE, Atlanta, GA 30322, USA;(4) Division of ECMO and Advanced Technologies, Children’s Healthcare of Atlanta at Egleston, Atlanta, GA, USA;(5) Division of Clinical Research, Children’s Healthcare of Atlanta at Egleston, Atlanta, GA, USA;(6) Pediatric Critical Care, Nemours Children’s Clinic, Pensacola, FL, USA;
Abstract:Background/purpose  Children receiving extracorporeal membrane oxygenation (ECMO) for respiratory failure can have significant fluid overload and renal insufficiency. Addition of inline continuous venovenous hemofiltration (CVVH) could provide additional benefits in fluid management compared to use of standard medical therapies with ECMO. Methods  Patients with pediatric respiratory failure receiving ECMO with CVVH were case-matched to similar patients receiving ECMO without CVVH to compare fluid balance, medication use, and clinical outcomes. Results  Twenty-six of eighty-six patients with pediatric respiratory failure on ECMO (30%) received CVVH for >24 h (median 7.5 days on CVVH). Survival was not significantly different between patients receiving CVVH and those who did not receive CVVH (P = 0.51). For ECMO survivors receiving CVVH, overall fluid balance was less than that in non-CVVH survivors (median 25.1 ml kg−1 day−1; range −40.2 to 71.2 vs. 40.2, 1.1 to 134.9; P = 0.028). Time to desired caloric intake was faster in patients receiving CVVH (1 day, 1–5) than in patients who did not receive CVVH (5 days; 1–11; P < 0.001). Patients receiving CVVH–ECMO also received less furosemide (0.67 vs. 2.11 mg kg−1 day−1; P = 0.009). Conclusions  Use of CVVH in ECMO was associated with improved fluid balance and caloric intake and less diuretics than in case-matched ECMO controls.
Keywords:Respiratory failure  Continuous venovenous hemofiltration  Extracorporeal  Hemofiltration  ECMO  Renal failure  Pediatrics  Continuous renal replacement therapy
本文献已被 PubMed SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号